Orphazyme closes its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe
Oct 1, 2020
With reference to the company announcement no. 52/2020, no. 54/2020, no. 55/2020, no. 57/2020 and no. 58/2020, Orphazyme A/S (ORPHA.CO) (“Orphazyme”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces the registration of the share capital increase of 7,616,146 new ordinary shares of nominal DKK 1 per share with the Danish Business Authority. The capital increase was registered in connection with the closing of the global offering (excluding the additional 1,142,421 ordinary shares (which may be in the form of ADSs or ordinary shares) that the underwriters have an option to subscribe for and purchase).
Orphazyme closes its global offering
Read moreOrphazyme files final prospectus in connection with a global offering, consisting of initial public offering of American Despositary Shares in the United States and concurrent private placement of ordinary shares in Europe
Sep 30, 2020
With reference to company announcements no. 52/2020, no. 54/2020 and no. 55/2020, Orphazyme A/S (ORPHA.CO) (“Orphazyme”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, announces that it has filed a final prospectus with the U.S. Securities and Exchange Commission (the “SEC”) for the global offering of 7,616,146 new ordinary shares, consisting of an initial public offering of 3,966,146 American Depositary Shares ("ADSs") representing ordinary shares of the Company in the United States (the "U.S. Offering") and a concurrent private placement of 3,650,000 ordinary shares in Europe (the "European Private Placement" and together with the U.S. Offering, the "global offering").
Orphazyme files final prospectus in connection ...
Read moreOrphazyme publishes a prospectus regarding listing of 7,616,146 new ordinary shares on Nasdaq Copenhagen in connection with a global offering
Sep 30, 2020
With reference to company announcements no. 52/2020, no. 54/2020 and no. 55/2020, Orphazyme A/S (ORPHA.CO) (“Orphazyme”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces the publication of a listing prospectus which has been approved by the Danish Financial Supervisory Authority (the “Listing Prospectus”) for the admission to trading and official listing of 7,616,146 new ordinary shares of nominal value DKK 1 per share (the “Listing Shares”) on Nasdaq Copenhagen under the symbol “ORPHA” (the “Listing”). A copy of the Listing Prospectus is available at www.orphazyme.com, and physical copies may be obtained within business hours at the offices of Orphazyme at Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark.
Orphazyme publishes prospectus ...
Read moreStabilization period begins
Sep 29, 2020
With reference to company announcement no. 55/2020 dated September 29, 2020 regarding the pricing of the global offering (the “Global Offering”), consisting of an initial public offering of American Depositary Shares (the "ADSs"), each such ADS representing one ordinary share (the “Ordinary Shares”) of Orphazyme, on the Nasdaq Global Select Market in the United States under the symbol "ORPH" (the "U.S. Offering"), and a concurrent private placement of Ordinary Shares in Europe traded on Nasdaq Copenhagen A/S under the symbol “ORPHA” (the “European Private Placement”), Orphazyme A/S ("Orphazyme") has received notification regarding the beginning of the stabilization period from BofA Securities, Inc., who is acting as stabilizing manager in the Global Offering for the ADSs traded on the Nasdaq Global Select Market in the United States and the Ordinary Shares of Orphazyme traded on Nasdaq Copenhagen A/S, respectively. Reference is made to the attached notice from BofA Securities, Inc., given on its and its affiliate, BofA Securities Europe SA, behalf to Orphazyme.
Read moreOrphazyme prices its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe
Sep 29, 2020
With reference to the company announcement no. 52/2020, dated September 21, 2020, pursuant to which Orphazyme A/S (ORPHA.CO) (“Orphazyme”) announced the filing of a F-1 registration statement, including a preliminary prospectus, and commencement of the global offering, and with reference to the company announcement no. 54/2020, pursuant to which Orphazyme provided an update on the previously announced global offering, Orphazyme, a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces the pricing of the global offering, consisting of an initial public offering of 3,966,146 ADSs on the Nasdaq Global Select Market (“Nasdaq”) at the public offering price of USD 11.00 per ADS (equivalent to a subscription price of DKK 70.1844 per ordinary share using a DKK/USD exchange rate of 6.3804), each such ADS representing one ordinary share of Orphazyme, and a concurrent private placement of 3,650,000 ordinary shares in Europe at a subscription price of DKK 70.1844 (together with the initial public offering in the United States, the “global offering”).
Orphazyme prices its global offering consisting of ...
Read moreOrphazyme A/S provides update on previously announced global offering
Sep 25, 2020
Orphazyme A/S (ORPHA.CO) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced an update on its previously announced global offering. On September 24, 2020, the Company received a filing communication from the U.S. Food and Drug Administration (FDA) in connection with its new drug application (NDA) for arimoclomol for the treatment of Niemann-Pick disease Type C. The FDA letter follows acceptance on a Priority Review basis by the FDA of the Company’s NDA for arimoclomol in NPC and the FDA’s establishment of the Prescription Drug User Fee Act (“PDUFA”) target action date of March 17, 2021. The Company’s receipt of the filing communication does not impact the FDA’s acceptance of the Company’s NDA, the target PDUFA action date or the FDA’s Priority Review determination.
Orphazyme as provides update on previously announced
Read moreNew incentive program for the Board of Directors of Orphazyme
Sep 21, 2020
Orphazyme A/S (ORPHA.CO) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the Company introduces a new Board Incentive Program for the Company’s members of the Board of Directors, as approved at the Company’s Extraordinary General Meeting held on September 21, 2020.
New incentive program for the board of directors of
Read moreOrphazyme A/S commences a global offering, consisting of initial public offering of ADSs in the U.S. and concurrent private placement of ordinary shares in Europe
Sep 21, 2020
Orphazyme A/S (ORPHA.CO) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that it has commenced a global offering of up to 7,616,146 new ordinary shares, consisting of an initial public offering of American Depositary Shares ("ADSs") representing ordinary shares of the Company in the U.S. (the "U.S. Offering") and a concurrent private placement of ordinary shares in Europe (the "European Private Placement" and together with the U.S. Offering, the "Offering").
Orphazyme as commences a global offering
Read moreResolutions passed at the Extraordinary General Meeting
Sep 21, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering the -Shock Protein response for the treatment of neurodegenerative orphan diseases, today held an Extraordinary General Meeting, at which the Extraordinary General Meeting.
Resolutions passed at the extraordinary general meeting
Read moreOrphazyme announces U.S. FDA acceptance and Priority Review of New Drug Application for arimoclomol for Niemann-Pick disease Type C
Sep 16, 2020
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted, with Priority Review, the company’s New Drug Application (NDA) for arimoclomol for the treatment of NPC.
Orphazyme announces u s fda acceptance and priority
Read more